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Comparison of Methods for
■<|««Measurement of Na /Li 
Countertransport Across the 
Erythrocyte Membrane
To the Editor:
About 30% of patients with insulin- 
dependent diabetes mellitus develop 
diabetic nephropathy. Since diabetic 
nephropathy contributes to a large 
extent to the high mortality of these 
patients, a risk marker for the devel­
opment of this condition is desirable. 
Increase in Na+/L i+ countertrans­
port across the red cell membrane 
has been suggested as such an early 
marker [1-4], although this was not 
uniformly confirmed [5-7]. In this
main methods to
were
s tudy, the
load erythrocytes with Li 
compared and tested for their mea­
suring error and intrasubject varia­
tion of Vmax and K0 5 for Na+.
The "classic" LiCi loading [8, 9] is 
the most "physiological" and nonin- 
vasive method. However, the load­
ing procedure takes 3 h, which pre­
cludes the use of this method as a 
standard procedure. The Li2C 03 
loading as described by Elving et al. 
[6] has the advantage that it takes 
only 30 min to load the cells with Li+. 
The Li'1 enters the cell via the 
HC03 /CF exchanger as a LiC03"~ 
ion in exchange for a Cl" ion, which 
ains the fast Li+ loading. This 
method has been reported to give 
plots to which Michaelis-Menten ki-
[10]. The nystatin 
method was developed by Canessa 
et al. [11] because at 150 mmol/L  
Na 1 (the highest concentration that
netics
Participants in this study were Li2C 03 or nystatin method fit better 
four male patients with insulin-de- to Michaelis-Menten kinetics than 
pendent diabetes with diabetic ne- the data obtained with the LiCl
phropathy and four healthy method. This was a reason for us to
volunteers. The subjects had fasted continue with the methods involving
overnight before a blood sample was Li2C03 and nystatin,
taken. Next, the CV of the measuring
The efflux media for the erythro- error of the data obtained with the
cytes loaded with Li+ by using the Li2C03 or nystatin Li+ loading meth- 
LiCl or Li2C03 methods contained 
0-150 mmol/L N a d  150-0 mmol/L
ods was analyzed (with a paired t- 
test). At one day the same sample of
choline chloride, 1 mmol/L MgCI2, blood was analyzed twice (Table 1). 
10mmol/LTris-3-(N-morpholino)pro- It was assumed that the difference 
panesulfonic acid (MOPS) buffer pH was negligible between the "month-
7.4, 10 mmol/L glucose, and 0.1 
mmol/L ouabain. Na+ concentrations 
were 0, 10, 20, 40, 60, 80,100,120, and 
150 mmol/L. The sum of the concen­
trations of Na+ and choline was al-
to-month variation within one sam­
ple" and the measuring error. It was 
further assumed that differences be­
tween two methods were statistically 
independent from each other, both
ways 150 mmol/L. The efflux media between
for the erythrocytes loaded with Li+ -----
by using the nystatin method con­
tained 0-300 mmol/L NaCl and 
300-0 mmol/L choline chloride; the the measuring error of the V 
rest of the medium was the same.
and between 
months. For both methods the CV of 
the measuring error of the KQ 5 for 
Na+ did not significantly differ from
m ax
Used Na+ concentrations were 0, 20,
(nys­
tatin P = 0.21; Li2C 03 P = 0.29).
When the two methods are com-
40, 60, 80, 100, 120, 140, 160, 180, 200, pared, there seems to be no impor-
220, 240, 260, 280, and 300 mmol/L. 
Here the sum of the concentration of 
Na+ and choline was always 300 
mmol/L. Li+ concentrations were 
measured by atomic absorption spec­
trometry (Model 4100; Perkin-Elmer, 
Norwalk, CT). The Vmax and K0c val-
tant difference in the CV of the mea­
suring error of the values for Vmnx or 
. For the T/max the difference be-K0.5
tween the values obtained with the 
nystatin and Li2C03 method was 
0.6% (SD = 6.3, P = 0.79) and for the
K0.5 for Na the difference was
ues were determined or extrapolated
with the computer program Graphpad
5.3% (SD = 13.1, P = 0.29).
In addition, the intrasubject varia- 
Inplot version 4.0 (Graphpad software, tion was examined (Table '1). A blood 
San Diego, CA). A rectangular hyper- sample was taken three times, with 
bola (binding isotherm) was fitted intervals of 1 month. The samples
through the data. The following equa 
tion was used: V 
(B+[Na+]); A =
A*[Na+]/
K 0.5
From each subject a blood sample
were analyzed with both the Li2C03 
and nystatin Li+ loading methods. 
For both methods the intrasubject 
variation for the K05 for N a1 was
and the Vmax and the Kn* for Na0.5
can be used at an osmolarity of 300 was taken twice, with a time interval large. Table 1 shows that for all
mosmol/L), the extracellular binding of 1 month. The data were analyzed 
site for Na 1 is often not saturated.
drug were determined. R 2 (coefficient of method comparison of the values for
...... t------------ ----- - t---- ---- mem- determination), a marker for the fit of the CVs of Vmax and K0 5 for Na '
brane, the intra- and extracellular os- the curve to Michaelis-Menten kinet- gives a difference of 22.7% (SD
methods the V,lTmx is more constant 
than the i*C05. For the nystatin,
molarity can be raised to 600 ics, was calculated. When the LiCl
mosmol/L, so extracellular concen- method was used, 25% of the R2
trations of Na 1 up to 300 mmol/L values were <0.7, which indicates a 
can be used. Because of this, K05
19.9, P = 0.015) and for the Li2C03 
method the difference was 12.6%
(SD 15.0, P = 0.05). From Table 1 it
poor fit to Michaelis-Menten kinet- seems as if the variation of the V max
values can in principle be measured ics. There were no curves including values obtained from one individual
more accurately than with the other 
methods. We found, however, that 
even at this high Na'1 concentrations 
the Vim,x of diabetic patients is often 
hardly reached.
Hill plots that fitted better. The nys­
tatin method generated only one R2 
value <0.7, and with the Li2C03 
method all R2 values were >0.7. It is 
clear that the data obtained with the
is smaller when the nystatin method 
is used, although this trend could not 
be supported statistically (P = 0.09).
Until recently the Na ' /L i1 coun­
tertransport activity was measured
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Table 1. Measuring error and intrasubject variation of Ko s and Vmax when the nystatin loading or Li2C03 loading method is0.5 M,,M 'm ax
used.
Intrasubject variation Measuring error
Mean
Method Value (Median) SD (95% confidence Interval) SD (95% confidence Interval)
'max 540 68
OO 57 Y yt)
(457) (3.4-12.8) (3.9-11.5)
^0.5 74 24 30.8C 10 q 1 àV  ♦  M u r
(76) (15.1-45.1) (4.0—14.2)
Nystatin *150 378 70 16.6 27 7.1'’
(324) (8.5-23.4) (2.3-11.9)
Knax 533 127 18.4® 38 7.1'
(455) (7.6-29.2) (3.7-10.5)
"0.5 89 32 31.0* 16 14.3"
(76) (19.4-42.6) (6.8-21,8)
U2CO3 '150 339 43 11.7 11 4.4
(292) (4.9-18.5) (1.6-7.2)
The P-values for the differences between the CVs were:1* vs  ^p ^ 0.015; b vs d P = 0.21; » vs * P -  0.049; 'vs " P ~  0.09; ‘"vs «P  0.09; * vs f P 0.79;
« vs * p = 0,98; d vs h P = 0.29, The mean values for Vmax, K03 for Na f , and V1BQ were 392, 43, and 311 respectively, when the LiCl method was used, The Vnm 
values and the values for K0>5 for Na+ obtained with the U2C03 method did not differ significantly from those obtained with the nystatin method {P ; 0.21 and 0,08), 
The values for Vm&K and K0,$ for Na'1" obtained with the LiCl method differed significantly from both the nystatin and LiaC0a method; P <0.001 for the Vimx and P -
0.016 for K03 for Na* when nystatin and LiCt are compared, P <0.001 for both the Vmox and the K0M when Li2C03 and LiCl are compared.
MM mmp I W B p W l l i i W »!■ iiiwiii m n m r r r - |  m u m  i u m il im i
as the Li efflux rate in medium 
containing 150 mmol/L Na+ after 
subtraction of the efflux rate in N a+- 
free medium. LiCl was used to load
and the Vrmax have been reported
[13,14], If Vmax and Kos are to be 
used as risk markers, new cutoff val­
ues for abnormal Na+/Li+ counter-
method with nystatin method
and they concluded that at 
mmol/L NaCl the maximum activity 
is not always reached, and that the re­
erythrocytes. As a discriminatory transport activity have to be estab- fore the nystatin loading method is
value, 400 jamol Li+/[h*L red blood lished.
cells (RBC)] was used. Subjects with
to be preferred. But none of these
Both the Li2C03 and nystatin load- studies compared all three methods
a countertransport above this value ing methods result in higher values 
were described as at risk. The values for K0>5 and than those obtained 
we found for the mean Na+/L i+ 
countertransport at 150 mmol/L  
Ha4 for the healthy individuals,
1
variation of the values
with the LiCl method (P <0. 
reason for this is unknown. One pos­
sible explanation could be that load-
obtained.
Lind Lant [17] and Wierz-
bicki */!
measured with the LiCl load- ing with Cl means exchange of whether nystatin will be removed by
ing [mean 225 /xmol Li+*(h*L HCO3 for Cl.via the band 3 anion washing. The fact that the mean val-
RBC) ]], are below this cutoff value. transporter. This could lead to pH ues of our results obtained with both
The values obtained with the Li-, CO 
method or the nystatin method are could
in the erythrocyte,
f1........-  N a 1 /  L i 4 -
the 
met
Li.,CO
do not differ a t
higher/ although <400 jamol Li4 / transport. Elving et al., however, re- the erythrocyte membranes are not
(h*L RBC) [260 and 312 /xmol L i1 / ported that
(h*L RBC)]. For the
damaged when nystatin is used. The
group
were m(diabetic and nondiabetic patients) 
the values for V150 are significantly loaded with either Li2C 03 or LiCl/6/.
the intracellular HC03 and Cl con- same authors as well as Thomas et al.
[19] questioned whether the data ob
two of the 
methods are compared. The V
is
151V
as ahowever, has been 
marker because it was reported that 
at 150 mmol/L N af the Vmax was 
often not reached. Our results con­
firm, this. Measurement of V
mal internal Li concentration is not
in all experiments by
by Zerbini et al. I Ui I fit to
is.M eilten kinetics. We
the data obtained
Li,CO
et al. [151 already compared 
the LiCl method with the Li-,CO
fit to
max and
KQ 5 for Na+ could give more reliable 
values. Moreover, as Rutherford et
method. In contrast to the present 
study, they found no difference in
data obtained with the LiCl
Vmax ^  K 0.5 But
al. [12] already mentioned, any dif- concluded that the Li2C03 method 
ferences in V150 observed can be due was to be preferred because this
to differences in either V m a x or K0.5
In addition, changes in both the K0r
method takes considerably less time. 
Zerbini et al. [16] compared the LiCl
Rutherford 
tuiges in K03 for Na 
VmtJX are the
creased V
t h a t  
a t h e r  t h a n  in
1 f5l>
e:
N a f / Li
anation
I eountertrans-
s pane
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[14]. This could be due to changes in 
binding of Na+, but may also reflect 
changes in translocation rate of the 
transporter. But because of the large 
fluctuations of the K05 for Na+ 
within one subject over time (inter­
vals of 1 month), it is doubtful 
whether the K0 5 can be used to iden­
tify patients at risk for development 
of diabetic nephropathy.
To conclude, in this study the ef­
fect of different Li"1" loading methods 
(LiCl, Li2C 03, or nystatin) on the 
reproducibility of the Ka5 and V max 
values for Na ' /Li'1 exchange were 
compared. The LiCl method gener­
ates N a '/L i'1’ exchange activities 
that often do not apply to Michaelis- 
Menten kinetics. Our results suggest 
that both the nystatin method and 
the Li2C 03 method are preferred 
over the LiCl method.
We are grateful to the Dutch Diabe­
tes Fund for supporting this work 
(grant 92.602).
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Antioxidant Activity of the Stilbene 
Astringin, Newly Extracted from Vitis 
vinifera Cell Cultures
To the Editor:
Numerous epidemiological studies 
in France have shown a strong neg­
ative correlation between moderate 
red wine consumption and the inci­
dence of cardiovascular disease
beverages, red wine contains a much 
higher content of phenolic constitu­
ents. Frankel et al. [31 have shown 
that total phenolic compounds ex­
tracted from red wine inhibit the 
oxidation of human low-density li­
poprotein (LDL) in vitro, which may 
provide an explanation for the 
"French paradox." In fact, increasing 
evidence suggests that oxidized LDL 
might be responsible for promoting 
atherogenesis.
Miller and Rice-Evans [4] exam­
ined a variety of red wines for total 
antioxidant activity and, based on 
the data of Frankel et al. [5] for the 
composition of wine, suggested that 
unidentified compounds must con­
tribute to this total.
With the help of Vitis vinifera cell 
suspension obtained from Gamay 
Teinturier vine-plant, we isolated 
and characterized stilbenes (c/s- and 
irans-piceid and trans-resveratrol)
and anthocyanins (malvidin-3-0-/3- 
glucoside and peonidin-3-0-/3-glu- 
coside) by spectrometric methods. 
Furthermore, we found evidence of 
production of astringin (a stilbene), 
which has never been reported as a 
constituent of Vitis vinifera and of 
wines [6,7]. Here, we report our 
study the antioxidant potency of 
these compounds isolated from Vitis
tion of lipid peroxidation induced by 
Cu2 1 (IC50 = concentration at which 
one-half of the induced peroxidation 
is inhibited) in fresh human LDL 
preparation; we determined this by 
measuring the production of thiobar- 
bituric acid-reactive substances [8]. 
The lack of interference from the 
coloration of anthocyanins is verified 
by HPLC assays.
The IC50 of ira/zs-resveratrol (Table 
1) is of similar magnitude to that
